Evidence map›Paper›PMID 42329011›Full record

ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2026

Outcomes of Lung Transplantation for Pulmonary Sarcoidosis Across Multiple Eras: A 25-Year Experience from a US Center.

Zein Kattih, Abhimanyu Chandel, Vikramjit Khangoora, Jared Wilkinson, Alan Nyquist, Anju Singhal, Christopher Thomas, Silpa Kilaru, Christopher King, Oksana Shlobin and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zein KattihAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.ORCID 0000-0002-9486-1674
Abhimanyu ChandelDepartment of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
Vikramjit KhangooraAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.
Jared WilkinsonAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.
Alan NyquistAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.
Anju SinghalAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.
Christopher ThomasAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.
Silpa KilaruAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.
Christopher KingAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.
Oksana ShlobinAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.
Steven NathanAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.
Shambhu AryalAdvanced Lung Disease and Transplantation Program, Inova Schar Heart and Vascular Institute, Inova Health System, Falls Church, Virginia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimSarcoidosis is a systemic condition with various clinical manifestations including end-stage lung disease. The aim of this study was to evaluate the characteristics and outcomes of patients with sarcoidosis undergoing lung transplantation.

methodsA single center retrospective review was performed of 63 sarcoidosis patients who underwent lung transplantation between January 1, 2000 and April 30, 2025. Patients were divided into arbitrary eras by year (Era 1 2000-2007; Era 2 2007-2013; Era 3 2013-2025).

resultsThe median age of the cohort was 53 years, 51% were female, 79% were black, 33% had blood type A, and the median body mass index was 24.4 kg/m2 (21.3-28.2). The majority (93%) of patients had pulmonary sarcoidosis stage IV by Scadding staging, and 89% had pulmonary hypertension. Baseline median six-minute walk test distance (6MWD) was 235 m (133-306). The median FVC% was 45% (34-50), median FEV1 was 37% (26-45), median- FEV1/FVC was 73% (62-83) and median DLCO% was 26% (18-32). The median mean pulmonary artery pressure (mPAP) was 35 (26-44) mmHg, and the median pulmonary vascular resistance (PVR) was 4 (3-6) Wood Units (WU). Chronic lung allograft dysfunction (CLAD) occurred in 38% of patients at a median 85 months post-transplant. Overall survival was 87.6%, 66% and 50.6% at 1, 3, and 5 years, respectively. There was no statistically significant difference in mortality across eras: era 1 vs era 3 (HR 0.888, 95% CI 0.407-1.94, p=0.766).

conclusionsOutcomes of sarcoidosis patients who undergo lung transplantation are similar to patients with other underlying diagnoses. Timely referral should be made to specialized centers.

Identifiers

PMID42329011
PMCPMC13359002

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.